Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.

J Parkinsons Dis · 2025 · PMC13347414 · PMID 39973479

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Efficacy (SKY) For the primary endpoint of motor function (change from baseline to month 9 in MDS-UPDRS Part III score), all dosage groups, whether ITT or PP population, showed worsening over the 9-month treatment period, except for the 600 mg group with a nonsignificant trend toward improvement ( Table 2 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.